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In our recently published meta-analysis, due to an oversight, we treated urinary As concentration
data reported by Tsinovoi et al. [1] instead as drinking water As data. This oversight impacted, in minor
way, our linear and non-linear published dose-response models for combined fatal and non-fatal strokes.
The oversight does not impact, in any way, any of our other published [2] dose-response models.
We corrected both Table 1 and Supplementary Materials Table S1; the exposure media for
Tsinovoi et al. [1] is changed to ‘urinary As (µg/g creatinine)’ from ‘water As (µg/L)’. Accordingly, we
modified dose-response models (Table 2) and goodness of fit parameters (Table 3) for the relationships
between drinking water As and combined fatal and non-fatal risks of strokes in the corrected
Manuscript [2]. These are based on using Equation (3) of Xu et al. [2] to calculate equivalent drinking
water As concentrations from the reported urinary As values from Tsinovoi et al. [1]. Over the drinking
water arsenic concentration range 1 to 50 µg/L, the absolute differences between the originally published
and corrected relative risks (RR) for the linear and non-linear dose-response models for combined fatal
and non-fatal stroke risks are all < 0.001 and < 0.020 respectively.
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Table 1. Characteristics of studies included for dose-response meta-analysis.











0.1–12.0 2.3 1 (referent)
16 19,109 12.1–62.0 34.0 1.22 0.56 2.65
15 18,699 62.1–148.0 101.0 1.49 0.70 3.19





< 10 7.4 1 (referent)
573 713,276 10–20 12.9 1.40 1.19 1.64





< 1 0.7 1 (referent)
19,709 4,803,000 1–10 3.9 1.05 1.01 1.10






< 5.8 4.2 1 (referent)
67 13,430 5.8–9.7 7.5 0.99 0.70 1.41
87 12,720 9.8–15.7 12.4 1.18 0.83 1.69





< 10 5 1 (referent)
5 1417 10–500 255 3.30 0.80 13.69





0–5 1.1 1 (referent)
26 9047 5.1–20 11.8 1.07 0.64 1.78
72 21,367 20.1–100 26.2 1.22 0.82 1.82
17 3313 100.1–300 156.1 1.55 0.88 2.73





0.01–0.07 0.05 1 (referent)
51 852 0.07–0.11 0.09 1.13 0.77 1.67






0.1–12.0 2.3 1 (referent)
51 19,109 12.1–62.0 34.0 1.21 0.80 1.84
41 18,699 62.1–148.0 101.0 1.24 0.80 1.93





< 10 0.7 1 (referent)
168 139,233 10–49 31.8 1.03 0.82 1.29
463 365,496 50–149 95.0 1.16 0.96 1.40
318 241,930 150–299 201.2 1.23 1.01 1.51





< 10 7.4 1 (referent)
2115 713,276 10–20 12.9 1.28 1.08 1.51
3514 904,129 > 20 29.7 1.36 1.06 1.74
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Table 1. Cont.









< 1 0.7 1 (referent)
62,739 4,803,000 1–10 3.9 1.02 0.99 1.06






< 5.8 4.2 1 (referent)
95 13,430 5.8–9.7 7.5 1.12 0.83 1.52
115 12,720 9.8–15.7 12.4 1.26 0.92 1.73





0–5 1.1 1 (referent)
42 9047 5.1–20 11.8 0.72 0.32 1.60
113 21,367 20.1–100 26.2 0.79 0.34 1.86
24 3313 100.1–300 156.1 0.62 0.10 3.70





0.01–0.07 0.05 1 (referent)
103 1691 0.07–0.11 0.09 1.04 0.80 1.35





<10 5.0 1 (referent)
84 2130 10–49 29.5 0.95 0.74 1.21
116 2317 50–499 274.5 1.34 1.08 1.66






< 10 7.4 1 (referent)
448 713,276 10–20 12.9 1.33 1.12 1.58





0.01–0.07 0.05 1 (referent)
16 243 0.07–0.11 0.09 1.28 0.64 2.61





< 10 1.7 1 (referent)
196 156,362 10–49 21.1 1.20 0.92 1.57






< 5.8 4.2 1 (referent)
17 13,430 5.8–9.7 7.5 1.41 0.54 3.67
13 12,720 9.8–15.7 12.4 2.16 0.77 6.09





0.1–12.0 2.3 1 (referent)
26 19,109 12.1–62.0 34.0 1.35 0.75 2.43
18 18,699 62.1–148.0 101.0 1.20 0.63 2.27





0–5 1.1 1 (referent)
16 9047 5.1–20 11.8 0.47 0.27 0.84
41 21,367 20.1–100 26.2 0.51 0.34 0.79
7 3313 100.1–300 156.1 0.25 1.10 2.95
1 249 Over 300 387.9 1.02 0.16 6.71
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Table 1. Cont.









< 1 0.7 1 (referent)
18,327 4,803,000 1–10 3.9 1.00 0.99 1.05
3895 1,011,000 > 10 23.3 1.02 0.95 1.09
Fatal and non-fatal
Carotid atherosclerosis disease





≤ 50.00 25 1 (referent)
46 95 50.01–100.00 75 1.90 0.90 3.80






< 10 5 1 (referent)
23 61 10.1–50 30 1.80 1.00 3.20






< 10 5 1 (referent)
31 81 10.1–50.0 30 1.53 0.67 3.50







< 10 1.9 1 (referent)
105 236 10–39 16.0 1.23 0.78 1.93






< 5.8 4.2 1 (referent)
206 11,701 5.8–9.7 7.5 1.05 0.86 1.28
197 11,305 9.8–15.7 12.4 0.95 0.77 1.19





1–20 5.7 1 (referent)
18 1335 20–30 25.3 1.25 0.70 2.31
16 534 30–45 35.1 2.14 1.22 3.98





0.1–25 5.1 1 (referent)
72 2718 25.1–107 57.0 1.18 0.75 1.84







< 5.8 4.2 1 (referent)
297 11,701 5.8–9.7 7.5 1.14 0.95 1.35
291 11,305 9.8–15.7 12.4 1.05 0.87 1.26





0.1–25 5.1 1 (referent)
120 2718 25.1–107 57.0 1.00 0.67 1.50






< 538 269 1 (referent)
103 721 538–700 619 1.18 0.60 2.34
83 634 > 700 781 0.83 0.40 1.68
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Table 1. Cont.









< 4.2 2.1 1 (referent)
451 1057 4.2 to 8.3 6.3 1.08 0.83 1.40
446 1090 > 8.3 to 17.1 12.7 1.30 0.94 1.80






0.1–8.0 2.8 1 (referent)
274 2116 8.1–40.8 23.2 1.10 0.90 1.33
273 2187 40.9–91.0 63.9 1.03 0.85 1.25
259 2181 91.1–176.0 128.1 1.01 0.83 1.22






10–22 15.5 1 (referent)
19 208 23–32 27.5 1.33 0.67 2.62
13 252 33–261 180.0 1.10 0.49 2.44
12 243 ≥ 262 376.0 0.96 0.42 2.23





< 100 61.0 1 (referent)
30 119 100 to 350 223.8 1.20 0.63 2.29






< 25.5 12.8 1 (referent)
106 260 25.5–47.9 36.7 1.30 0.84 2.00
109 259 47.9–79.0 63.5 1.27 0.82 1.94
118 259 ≥ 79.0 94.6 1.41 0.91 2.17





< 60 30.0 1 (referent)
246 482 60–859 459.5 1.33 0.98 1.79






< 0 2 1 (referent)
50 623 0–500 250 1.20 0.60 2.30
93 576 500–1000 750 2.20 1.10 4.30







2.72–3.72 3.3 1 (referent)
138 622 4.75–5.88 5.3 0.97 0.73 1.30
139 624 8.26–9.18 8.1 1.03 0.77 1.38
119 606 11.99–16.72 13.9 0.87 0.64 1.18






< 5.8 4.2 1 (referent)
75 11,701 5.8–9.7 7.5 1.18 0.82 1.69
62 11,305 9.8–15.7 12.4 1.16 0.77 1.72





0.1–25 5.1 1 (referent)
46 2718 25.1–107 57.0 0.86 0.49 1.51
52 2770 108–864 198.5 1.38 0.84 2.27
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Table 1. Cont.









0.049–0.573 0.435 1 (referent)
657 180,891 0.573–0.760 0.584 1.21 1.07 1.36
475 169,470 0.760–1.933 1.174 1.05 0.92 1.19
577 173,856 1.933–25.34 2.109 1.17 1.04 1.32
CVD markers






0.1–8.0 2.8 1 (referent)
252 2116 8.1–40.8 23.2 1.39 1.14 1.71
232 2187 40.9–91.0 63.9 1.21 0.99 1.49
227 2181 91.1–176.0 128.1 1.19 0.97 1.45






10–22 15.5 1 (referent)
10 208 23–32 27.5 3.87 1.22 12.2
10 252 33–261 180.0 4.32 1.23 15.11






0.1–9 2.8 1 (referent)
63 432 9.5–57 30.0 1.10 0.74 1.63
49 423 58–144 95.1 0.87 0.57 1.31






< 21 10.7 1 (referent)
12 108 100–350 199.9 3.83 1.13 12.99
21 102 430–690 568.3 8.85 2.72 28.75
CVD: cardiovascular disease; CHD: coronary heart disease. RR: Relative risk or approximation of the relative risk (rate ratio, risk ratio, odds ratio). ir: Risks estimated in the studies as
rate ratio (incidence-rate data); ci: Risks estimated in the studies as risk ratio (cumulative incidence data); cc: Risks estimated in the studies as an odds ratio (see details reported by
Orsini et al. [65]).
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Table 2. Pooled relative risks (95% CIs) for different types of cardiovascular disease (CVD) and clinic markers in relation to water arsenic concentrations.
Mortality Risk Combined Fatal and non-Fatal Risk CVD Markers
CHD (7(25)) a CVD (8(31)) a Stroke(7(25)) a CHD (4(14))










Log-linear dose-response association model
1 µg/L b 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000































































































coefficient 0.175 0.070 0.054 0.148 0.150 0.046 0.287 0.090 0.156 0.282
p-value for trend c 0.003 0.005 0.510 < 0.001 < 0.001 0.090 < 0.001 0.014 0.320 0.290
I2 d 79.7% 77.9% 89.0% 6.6% 17.4% 0.0% 17.5% 62.3% 80.4% 91.5%
Cochran’s
Q-statistic 29.54 31.70 54.78 3.21 1.21 2.88 2.43 18.56 5.10 11.7
P-heterogeneity e < 0.001 < 0.001 < 0.001 0.360 0.271 0.409 0.297 0.097 0.024 0.006
Non-linear dose-response association model (restricted cubic splines)
1 µg/Lb 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000































































































p-value for trend f 0.006 < 0.001 0.750 0.047 0.078 0.390 < 0.001 0.200 0.150 0.270
I2 d 69.8% 35.3% 80.0% 41.0% 53.7% 0.0% 0.0% 46.3% 73.1% 72.5%
Cochran’s
Q-statistic 39.75 21.65 60.02 10.16 4.32 5.65 2.58 26.07 7.43 7.27
P-heterogeneity e < 0.001 0.086 < 0.001 0.117 0.115 0.460 0.629 0.025 0.024 0.026
CVD: cardiovascular disease; CHD: coronary heart disease. a: Sum of studies included; the total number of relative risks in each model. b: treat 1 µg/L water arsenic concentration as the
referent. c: p-value for linear trend from a Wald test of the coefficient for drinking water arsenic concentrations. d: Proportion of total variance due to between-study heterogeneity.
e: p-value for heterogeneity is chi-square p-value of the Q-statistic. f: Non-linear trend p-value for the non-linear spline coefficient in a model with arsenic concentrations entered as a
restricted cubic spline with knots at 10th, 50th and 90th percentiles of water arsenic concentration.
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Table 3. Goodness-of-fit assessment.
Studies
Mortality Risk Combined Fatal and non-Fatal Risk CVD Markers





Log-linear dose-response association model
Deviance a 19.40 22.58 15.98 13.04 7.06 18.53 2.99 20.27 14.02 4.97
Degrees of freedom b 17 22 17 9 4 11 5 21 6 4
p-value c 0.306 0.426 0.526 0.161 0.133 0.070 0.702 0.504 0.029 0.291
R2 0.320 0.258 0.027 0.537 0.798 0.134 0.844 0.230 0.066 0.185
Adjusted R2 0.280 0.225 −0.031 0.486 0.748 0.056 0.813 0.193 −0.089 −0.019
AIC 0.17 −6.77 6.58 −0.56 1.26 −2.22 3.38 −4.36 4.55 5.58
Non-linear dose-response association model (restricted cubic splines)
Deviance a 17.28 22.81 15.39 5.83 3.94 17.61 1.71 12.94 9.16 3.44
Degrees of freedom b 16 21 16 8 3 10 4 20 5 3
p-value c 0.367 0.354 0.496 0.666 0.267 0.062 0.789 0.880 0.103 0.328
R2 0.373 0.620 0.035 0.512 0.564 0.097 0.892 0.199 0.292 0.435
Adjusted R2 0.297 0.584 −0.085 0.390 0.273 -0.084 0.838 0.118 0.008 0.058
AIC 29.95 5.89 23.86 12.34 10.37 16.07 13.75 23.55 12.16 11.43
CVD: cardiovascular disease; CHD: coronary heart disease. a: Measure of the total absolute deviation between reported and predicted log-relative risk taking into account the covariance
structure of the residuals. b: Degrees of freedom from the deviance statistic. c: p-value from test for model specification. AIC: Akaike’s information criterion.
Int. J. Environ. Res. Public Health 2020, 17, 8947 9 of 11
We also made the required corrections in Figures 1 and 2 and Supplementary Figure S2, although
these are almost identical to the original figures.
Figure 1. Individual study dose-response characteristics for various CVD subtypes or biomarkers.
Arsenic concentrations refer to the observed or estimated median arsenic concentrations for the given
concentration category. Lines connect the dose-response data for each study and are for illustrative
purposes only (CVD: cardiovascular disease; CHD: coronary heart disease).
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Figure 2. Pooled log-linear and non-linear relative risks and 95% confidence intervals (CIs) of different
CVD endpoints in relation to the estimated drinking water arsenic concentration. Pooled log-linear and
non-linear relative risks of CVD endpoints were estimated for drinking water arsenic concentrations
with reference to an arsenic concentration of 1 µg/L. Solid lines (red) correspond to pooled relative
risks of linear models with their 95% CIs represented as shaded regions (red). Pooled relative risks
of non-linear models were represented by long-dash lines (blue) and their 95% CIs were plotted as
shaded areas (blue). Log-linear models were estimated with log-transformed estimated drinking water
arsenic concentration and non-linear associations were estimated from models with restricted cubic
splines of log-transformed water arsenic concentration with knots at the 10th, 50th and 90th percentiles
of log-transformed water arsenic (CVD: cardiovascular disease; CHD: coronary heart disease).
Lastly, we note that the corrections to the linear and non-linear dose-response models for combined
fatal and non-fatal risks of strokes as a function of drinking water arsenic concentration show the same
trends as in the original publication and, in particular, over the relatively low concentration range in
the scope of the study, there remains no significant association in the data collated between drinking
water As concentration and the combined fatal and non-fatal risks of stroke.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/17/23/8947/s1,
Figure S1: Flow diagram of study selection procedure, Figure S2: Association of CVD endpoints with drinking
water arsenic concentrations, Figure S3: Funnel Plots for the analysis of publication bias, Table S1: Epidemiological
studies of arsenic (As) exposure and cardiovascular disease (CVD) included in the systematic review, Table S2:
Egger’s regression test of funnel plot asymmetry, Table S3: Pooled relative risks (95% confidence intervals) for
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different CVD types and clinical markers in relation to drinking water arsenic concentrations with the exclusion of
studies which do provide drinking water As concentrations directly, Table S4: Pooled relative risks (95% confidence
intervals) for different CVD types and CVD markers in relation to drinking water arsenic concentrations lower
than 100 ppb.
Funding: LX was funded by the University of Manchester.
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